PubMed · 15299094
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Peter Gross, Frank Pistrosch. 2004. Hyperkalaemia: again.. https://doi.org/10.1093/ndt%2Fgfh284
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Afterload reduction is useful for treating and preventing adult congestive heart failure outside the realm of anthracycline toxicity. Afterload reducers are commonly used as treatment for acute heart failure associated with anthracyclines. However, the use of afterload reduction for the prevention of anthracycline associated late cardiomyopathy remains a controversial area, with strong opinions expressed concerning the potential risks and benefits of such an approach. This article will define "afterload" and the tools utilized to measure afterload. The study will then describe the theory for the use of afterload reduction in patients with anthracycline exposure who show signs of anthracycline cardiotoxicity, and will present data from the ACE-Inhibitor After Anthracyclines (AAA) Trial to help answer the question, "Should an afterload reducer be used to aid in preventing late anthracycline cardiotoxicity?" Finally, recommendations for future research will be presented.
Explore the source record for details and available documents.
Explore the source record for details and available documents.